
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is a commercial-stage medical device and biopharmaceutical company with a positive outlook. Their primary source of revenue is their LungFit platform, which uses NO generated from ambient air to treat respiratory conditions. Despite near-term monetization risks, the company's strategic objective of maximizing value from their assets through partnerships, licensing, or future transactions could still bring significant value to the company. The stockholder and employee risks mentioned may impact the company's bottom line, but overall they have a solid product and technology with potential for future growth.
Bears say
Beyond Air is entering a new phase with a transition in leadership, signaling a shift towards focusing on commercial execution and generating revenues through broader market adoption of its LungFit PH technology. This change in strategy, along with the potential monetization of its NeuroNOS platform, could bring in additional funds for the company and provide shareholders with greater optionality in the future. However, its current reliance on its LungFit platform for majority of its revenue and potential risks associated with its NeuroNOS platform could impact its financial performance in the short term.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares